“GSK in Belgium plays a key role in the fight against Covid-19 because the adjuvant that will be used in the vaccine will be produced in particular at the GSK site in Wavre, which is the largest vaccine production site in the world. The site in Wavre will contribute, along with other GSK sites, to the production of one billion doses of the adjuvant in 2021. In addition, the adjuvant technology was developed by GSK in Belgium, at Rixensart “GSK said in a statement on Friday evening. GSK and Sanofi are in advanced discussions with the European Union to provide up to 300 million doses of the vaccine against Covid-19. The European executive is also continuing “intensive discussions” with other vaccine manufacturers, it said in a statement. The two companies are committed to making their vaccine affordable and accessible worldwide.
“GSK is proud to work in partnership with Sanofi to make this vaccine available as quickly as possible in Belgium and Europe. The GSK sites in Belgium play a crucial role because not only the adjuvant technology has been developed by our historic site in research and development at Rixensart, but our largest vaccine manufacturing site in the world in Wavre will also contribute to the manufacture of one billion doses of adjuvants in 2021. GSK and Sanofi have research and development capacity and manufacturing in Europe and we are already working hard to increase production in all of our networks. This announcement by the European Commission supports our continued efforts “, said Patrick Florent, CEO of GSK Vaccines in Belgium .